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vidual variation in warfarin dosage.
Prospective studies that incorporate
both gene testing and a variety of
ethnic, clinical, pharmacological, and
environmental variables, along with
age, sex, and body weight, will be
required to demonstrate the real
safety, cost-effectiveness, and feasibil-
ity of individualized dosing regimens
according to the statistical models for
warfarin dose calculation.
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Evaluation of Analytical Performance
of the Siemens ADVIA TnI Ultra
Immunoassay
To the Editor:
In light of recommendations on the
quality (1 ) and clinical use (2 ) of
troponin assays, we evaluated the
analytical performance of the AD-
VIA Centaur and ADVIA CP® plat-
forms (TnI-Ultra, Siemens Medical
Solutions Diagnostics SrL) for mea-
surement of cardiac troponin I
(cTnI). The chemiluminescent TnI-
Ultra method uses 2 monoclonal cap-
ture antibodies directed to epitopes
at amino acids 41–49 and 87–91 and
a tracer polyclonal goat antibody la-
beled with acridinium ester, directed
against amino acids 27–40 (1, 3, 4 ).
Two clinical laboratories participated
in the study: the CNR Institute of
Physiology in Pisa and the San Bor-
tolo Hospital in Vicenza.
The limit of detection (limit of the
blank) for the TnI-Ultra method was
calculated as the concentration corre-
sponding to a signal of 3 SD above
the mean of 60 replicates (obtained in
4 different runs and pooled together)
for the calibrator in which cTnI was
absent; a mean cTnI concentration of
0.006 g/L was found. The total im-
precision (CV%) of the TnI-Ultra
method, assessed according to the
NCCLS EP5-A protocol over 20 con-
secutive working days, was 11.6%,
5.6%, and 4.4% for 3 plasma samples
with cTnI concentrations of 0.05,
0.25, and 2.68 g/L, respectively.
From plots of CV vs log-transformed
values of cTnI concentration in the
range 0.006–0.20 g/L, the cTnI con-
centrations that corresponded to 10%
CVwere 0.064 g/L for ADVIA Cen-
taur CP® and 0.07 g/L for ADVIA
Centaur.
Blood samples, collected in
polypropylene tubes with lithium
heparin, were used in the study, ac-
cording to the routine protocol
adopted by both clinical laboratories.
The 2 laboratories enrolled a white
population including 418 apparently
healthy adult individuals (204 men
and 214 women) with a mean (SD)
age of 50.7 (16.6) years, range 16–89
years; the mean (SD) age in women
was 52.6 (17.5) years and in men 48.7
(15.5) years. The presence of cardiac
or other acute or chronic diseases
was excluded by clinical examination
and laboratory tests. Informed con-
cent was obtained by all individuals
and patients before testing, and the
study protocol was approved by the
local ethics committee. The mea-
sured cTnI values approximated a
log-normal distribution with a calcu-
lated 99th percentile of 0.087 g/L;
therefore, the ratio of 10% CV con-
centration to 99th percentile limit for
the TnI-Ultra method was 0.067:
0.087  0.77 (1 ). In 82 samples, in-
cluding 81 females and only 1 male,
we found values 0.004 g/L (i.e.,
undetectable cTnI concentration),
and so an arbitrary concentration of
0.001 g/L was attributed to these
samples. A highly significant corre-
lation was found between cTnI val-
ues and age (R  0.268, P 0.0001 by
Spearman rank correlation coeffi-
cient test). Moreover, a significant
difference was found between the
cTnI values found in men and
women, respectively [mean (SD)
0.015 (0.018) g/L, median 0.012
g/L, range 0–0.196 g/L, n  204
for men; 0.009 (0.014) g/L, 0.008
g/L, 0–0.130 g/L, n  214 for
women; P 0.0001 by Mann–Whit-
ney U-test]. We found that both sex
(as a dummy independent variable
with F  1 and M  2) and age (as a
continuous independent variable) in-
dependently contributed to the re-
gression with cTnI (as a dependent
variable after log transformation of
original values) by using a stepwise
multiple regression analysis (log
cTnI  3.164  0.456 sex  0.007
age; P 0.0001, F-value  71.962,
R  0.508, n  416).
A close linear relationship was
found between cTnI values mea-
sured by ADVIA TnI-Ultra with the
Centaur CP® platform and the Ac-
cess AccuTnI method on the Uni-
Cell® DxI 800 platform (Beckman
Coulter) in 318 plasma samples of
155 apparently healthy individuals
and 163 cardiac patients (ADVIA
0.016  1.272 Access; R  0.936). The
TnI-Ultra method showed higher
cTnI values than the Access AccuTnI
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method (on average by 22.0%; P
0.0001 by Wilcoxon signed-rank
test) and based on the 99th percentile
values for each assay, 9 discordances
were found between assays for val-
ues within the reference interval vs
increased values.
The ADVIA TnI-Ultra method
showed no interference from dilu-
tions with plasma samples that con-
tained high concentration of triglyc-
erides (6.6 g/L, final dilution 1:128;
y  0.044  0.14x, n  8, R  0.99)
or hemoglobin (1.47 g/L, final dilu-
tion 1:4996; y 0.04 0.060x, n 13,
R  0.99). No apparent positive in-
terference was seen in 58 patients
with symptomatic rheumatoid ar-
thritis [10 men and 48 women, mean
(SD) age 60.8 (10.2) years] with a
mean concentration of rheumatoid
factor of 189.6 kIU/L (range 40–1280
kIU/L), because the mean (SD) cTnI
concentration was not increased
0.017 (0.023) g/L.
The present study indicates that
the ADVIA TnI-Ultra method meets
the quality specifications recom-
mended by NACB and IFCC Com-
mittee for the Standardization of
Cardiac Damage (5 ).
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Midtrimester Amniotic Fluid
Adiponectin in Normal Pregnancy
To the Editor:
Adiponectin is an adipose tissue–
derived protein with important met-
abolic effects and a strong correlation
with insulin sensitivity. In pregnancy
there is a progressive increase of in-
sulin resistance, whereas plasma adi-
ponectin concentrations decrease in
the 2nd half of gestation (1 ). In con-
trast, cord plasma adiponectin con-
centrations increase throughout ges-
tation (2 ). Nothing is known about
the concentration, origin, or role of
amniotic fluid adiponectin, particu-
larly in relation to amniotic insulin.
Therefore we evaluated adiponectin
and insulin concentrations in the
midtrimester amniotic fluid of
women with normal pregnancies.
Beginning January 1, 2006, we se-
lected the first 50 pregnant women
who underwent a midtrimester am-
niocentesis for prenatal diagnosis
(15–18 weeks gestation) and were
found to have a normal pregnancy,
defined as an uncomplicated preg-
nancy with full-term delivery of an
infant of adequate size for gesta-
tional age. The study was approved
by the institutional review board,
and all women gave written in-
formed consent.
Amniotic fluid samples were ob-
tained by transabdominal amnio-
centesis and collected in 15 mL dry
tubes. All samples were free of blood
contamination, as estimated by mi-
croscopic inspection. The samples
were immediately centrifuged for 10
min at 3000g and stored at –70 °C.
Plasma EDTA samples were centri-
fuged for 15 min at 1000g within 30
min of collection and stored at –70 °C.
Plasma samples required 200-fold di-
lution before assay. The adiponectin
concentration was measured by im-
munoenzymatic assay (R&D Systems).
The intra- and interassay imprecision
(CVs) for adiponectin at a concentra-
tion of 15.0 g/L were 3.5% and 5.5%,
respectively. The intra- and interassay
imprecision values (CVs) for insulin at
a concentration of 4.0 mIU/L were
3.3% and 5.6%, respectively.
Amniotic and plasma adiponectin
and amniotic insulin concentrations
are presented as the median and the
25th–75th percentile range; all other
variables are presented as the mean
(SD). The Mann–Whitney U-test was
used to compare continuous variables
between the 2 groups. Univariate cor-
relations between amniotic fluid adi-
ponectin and all the other variables
were assessed using the Spearman
test. The statistical analysis was per-
formed using SPSS 13.0 (SPSS Inc.). All
tests were 2-sided; a P value0.05was
considered statistically significant.
The clinical characteristics of preg-
nant women are reported in Table 1.
Median adiponectin amniotic fluid
values were 26.8 (13.9–37.3) g/L,
but when we dichotomized for sex,
there was a significant difference
(P  0.01) between female 34.8 (18.2–
48.7) g/L and male fetuses 18.2
(13.4–26.8) g/L. Univariate analysis
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